A French research team has found that the brain's metabolic activity, visible in scans already ordered for lung cancer patients, independently predicts survival in advanced non-small cell lung cancer — a disease that claims most of its metastatic patients within five months. The discovery reframes cancer not as a localized affliction but as a systemic condition in which the health of organs far from the tumor shapes a patient's fate. In doing so, it offers clinicians a way to hear what the body beyond the tumor has long been trying to say.
Low Brain Metabolism Predicts Worse Outcomes in Advanced Lung Cancer
Advanced non-small cell lung cancer patients face poor prognosis with median survival under five months in metastatic stages.